International consensus statement on allergy and rhinology: rhinosinusitis 2021
- PMID: 33236525
- DOI: 10.1002/alr.22741
International consensus statement on allergy and rhinology: rhinosinusitis 2021
Erratum in
-
Corrigendum.Int Forum Allergy Rhinol. 2022 Jul;12(7):974. doi: 10.1002/alr.22987. Epub 2022 Mar 11. Int Forum Allergy Rhinol. 2022. PMID: 35274477 No abstract available.
Abstract
I.
Executive summary: BACKGROUND: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR-RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR-RS-2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence-based findings of the document.
Methods: ICAR-RS presents over 180 topics in the forms of evidence-based reviews with recommendations (EBRRs), evidence-based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary.
Results: ICAR-RS-2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence-based management algorithm is provided.
Conclusion: This ICAR-RS-2021 executive summary provides a compilation of the evidence-based recommendations for medical and surgical treatment of the most common forms of RS.
Keywords: acute rhinosinusitis; chronic rhinosinusitis; endoscopic sinus surgery; evidence-based medicine; recurrent acute rhinosinusitis; rhinosinusitis; systematic review.
© 2021 ARS-AAOA, LLC.
Comment in
-
EDS-FLU: An important step in appropriate medical therapy for chronic rhinosinusitis with nasal polyps.Int Forum Allergy Rhinol. 2022 Jun;12(6):893-895. doi: 10.1002/alr.22998. Epub 2022 Apr 17. Int Forum Allergy Rhinol. 2022. PMID: 35348302 No abstract available.
-
Reply to "EDS-FLU: An important step in appropriate medical therapy for chronic rhinosinusitis with nasal polyps".Int Forum Allergy Rhinol. 2022 Jun;12(6):896-897. doi: 10.1002/alr.22999. Epub 2022 Apr 17. Int Forum Allergy Rhinol. 2022. PMID: 35353956 No abstract available.
References
REFERENCES
-
- Orlandi RR, Kingdom TT, Hwang PH, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S22-S209.
-
- Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177-1179.
-
- Yan C, Faraji F, Prajapati D, Boone C, DeConde A. Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol. 10(7):806-813
-
- Rudmik L, Smith TL. Development of an evidence-based review with recommendations using an online iterative process. Int Forum Allergy Rhinol. 2011;1(6):431-437.
-
- Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64(5):669-677.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical